MDZ Mds

Iconix Releases Updated Version 2.30 of DrugMatrix(TM) World's Largest Chemogenomics Reference Database & Informatics System MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire/ -- Iconix Pharmaceuticals, Inc. today announced the release of an updated version 2.30 of DrugMatrix(TM), the world's largest chemogenomics reference database and informatics system, offering increased data content and novel software features to enable drug discovery scientists to advance to the clinic compounds with the greatest probability of success. DrugMatrix 2.30 provides information for more than 1,000 drugs, including gene expression data, experimental molecular pharmacology profiles, curated literature information, and high-quality pathways based on primary literature. DrugMatrix offers the only chemogenomic reference database software system of its kind, with real integration of data including drugs and their structures, structural search capabilities, genomic data, gene annotations, bioassay data and literature information. The increased data content and novel software capabilities that are built into the new version provide researchers and scientists with expanded, more efficient tools. Some of the new features include: -- Support for data cartridge chemical structure search algorithms: making it easier for chemists using MDL Information System's cartridge product to use DrugMatrix by searching for chemical structures. -- Gene Expression Profile Query Tool: to quickly find the expression experiments most similar to a new compound's. -- Molecular Pharmacology Profile Query Tool: to easily identify molecular pharmacology patterns similar to a new compound's. -- Gene Ontology Analysis Tool: enables scientists to rapidly extract the key functional or pathway relationships from long lists of up- or down-regulated genes. -- Pathway Impact Analysis Tool: quickly identifies which pathways are affected by a new experimental compound. "The new version of DrugMatrix reflects the need for more sophisticated tools in drug discovery, and the integral role that chemogenomics now plays in the early stages of drug discovery and development," said Jim Neal, CEO of Iconix. About Iconix Iconix Pharmaceuticals, Inc. is pioneering the new field of chemogenomics, the integration of chemistry and genomics to profile drug candidates. Iconix's chemogenomic capabilities enable pharmaceutical companies to increase the odds of advancing the right compounds to the clinic, reducing attrition rates and the costs of drug discovery. Iconix provides reference systems and know-how to predict toxic liabilities and side effects of drug candidates, and determine if they are on or off target. The company has strategic partnerships with an ecosystem of leading life sciences companies, including MDS Pharma Services (TSE:MDS)(NYSE:MDZ), Incyte Corporation (NASDAQ:INCY) and Amersham Biosciences (LSE:OSE)(NYSE:AHM), and collaborations with Schering-Plough Research Institute (NYSE:SGP), Millennium Pharmaceuticals, Inc., and Eisai Co., Ltd. Iconix also provides research, training and support to the U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) under an agreement to advance CDER's study of the application of genomic technologies in the regulatory approval process. Headquartered in Mountain View, California, Iconix was founded in 1998 and is privately held. For more information visit iconixpharm.com. CONTACT: Peter Kojalo, +1-510-704-7777, ext. 12, or , for Iconix Pharmaceuticals, Inc. DATASOURCE: Iconix Pharmaceuticals, Inc. CONTACT: Peter Kojalo, +1-510-704-7777, ext. 12, or , for Iconix Pharmaceuticals, Inc. Web site: http://www.iconixpharm.com/

Copyright